Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

BPC-157 peptide: does it work, is it legal, and what does it cost?

A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about BPC-157
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: HHS interim policy (draft)

Not FDA approved. HHS's draft policy covers single-ingredient compounding under strict conditions. Blends are not covered. [16] [17] See legal status

What does it cost?No FDA approved product and no verified compounded price. Insurance does not cover it. See cost by channel
Side effects?No systematic human safety data; three small uncontrolled pilot reports (about 30 people in total) reported no adverse events. Injection site reactions reported anecdotally. Nausea and dizziness reported anecdotally. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is BPC-157?

BPC-157 is a lab-made chain of 15 amino acids (the building blocks of proteins) copied from part of a protein found in human gastric juice (stomach fluid). In rodents it consistently speeds tendon, ligament, muscle, and gut healing, but as of November 2026 there is no randomized human trial (one that assigns people to the drug or a placebo by chance) indexed in PubMed, so its evidence grade is animal-only. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient BPC-157 by injection under the skin or into muscle, by mouth, or on the skin on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add BPC-157 to the bulks list, and does not change its evidence grade.

BPC-157 is a synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound. It is also known as Body Protection Compound 157, Pentadecapeptide BPC 157, BPC 157, BPC-157 arginate, Bepecin, PL 14736, BPC157, BPC-157 peptide.

How does it work?

In animal and cell models BPC-157 upregulates growth factor receptors (including EGR-1 and its repressor NAB2), increases nitric oxide system activity, and promotes angiogenesis through VEGFR2 signaling. It also increases fibroblast migration and outgrowth from tendon explants. These mechanisms are documented in rodent and in vitro work and have not been confirmed in humans.

Key facts
ClusterTissue repair and healing
RoutesSubcutaneous injection (as sold); Oral capsule (as sold); Intraperitoneal, oral in water, and topical (animal studies)
Conditions studiedTendon injury and tendinopathy; Muscle recovery and injury; Wound healing; Inflammation and inflammatory bowel disease; Inflammatory bowel disease (Crohn disease and ulcerative colitis); Irritable bowel syndrome; Traumatic brain injury; Osteoarthritis; Chronic pain
Recordv3, reviewed, verified Nov 1, 2026

BPC-157 benefits: what the evidence shows

Evidence: Animal-only evidenceGrade assigned per the methodology.

Dozens of rodent studies from a small number of laboratories, mostly in Zagreb, report faster tendon, ligament, muscle, bone, and gastrointestinal healing, and a 2025 systematic review counted 35 preclinical studies and 1 clinical study in the musculoskeletal literature. Independent replication is limited. No randomized controlled trial in humans has been published as of the last verification date. The only indexed human data are three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety), which have no comparison group; they are listed but do not raise the grade.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies330
Animal studies6n/a
All indexed studies930

Human evidence

No randomized controlled trial identified. Three small uncontrolled pilot reports from a single clinic are indexed: a retrospective phone survey of 16 people given knee injections (12 BPC-157 alone, 4 combined with thymosin beta-4), in which 14 reported relief; a pilot in 12 women with interstitial cystitis given a single bladder wall injection, all of whom reported improvement; and a 2 person intravenous safety pilot that found no changes in heart, liver, kidney, thyroid, or glucose markers. None had a control group, blinding, or long follow-up. A 2025 narrative review described human data as extremely limited, and a 2025 systematic review found no clinical safety data.

Animal evidence

In rats, BPC-157 accelerated Achilles tendon healing and increased tendon fibroblast outgrowth, survival, and migration in explant models. Rodent studies also report faster healing of transected muscle, ligament, bone, and gastrointestinal lesions, and protection against NSAID induced gut injury, given by injection, orally in drinking water, or topically. In rats and endothelial cells it increased blood vessel growth and VEGFR2 expression. A pharmacokinetic study in rats and dogs found an elimination half-life under 30 minutes after intravenous or intramuscular injection, with rapid breakdown into amino acids.

Key studies

Indexed studies of BPC-157
StudyDesign and populationOutcomeGrade
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration2011 PMID 21030672Rat Achilles tendon transection model plus tendon explant and fibroblast cultureRats and rat tendon fibroblastsBPC-157 increased tendon explant outgrowth, fibroblast survival under stress, and cell migration; healing was faster in treated ratsEvidence: Animal-only evidence
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing2019 PMID 30915550Narrative review of animal and available human dataRodent studies of tendon, ligament, and muscle healingConsistent acceleration of soft tissue healing in rodents; human evidence limited to unpublished pilot work; authors call for human trialsEvidence: Animal-only evidence
Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications2016 PMID 27138887Narrative reviewRodent models of gut, brain, and vascular injurySummarizes proposed nitric oxide and growth factor mechanisms and cytoprotective effects across organ systems in animalsEvidence: Animal-only evidence
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract2011 PMID 21548867Narrative reviewRodent models of gastrointestinal lesions and fistulasReports healing of NSAID induced ulcers, fistulas, and anastomoses in rodents; notes oral and parenteral activityEvidence: Animal-only evidence
Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review2025 PMID 40756949Systematic review (36 studies: 35 preclinical, 1 clinical)Animal models of muscle, tendon, ligament, and bone injuryPreclinical studies reported better functional, structural, and biomechanical healing; half-life under 30 minutes; no clinical safety data foundEvidence: Animal-only evidence
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs2022 PMID 36588717Pharmacokinetic study after intravenous and intramuscular dosingRats and beagle dogsElimination half-life under 30 minutes; rapid metabolism into small peptide fragments and amino acids; excreted in urine and bileEvidence: Animal-only evidence
Intra-articular injection of BPC 157 for multiple types of knee pain2021 PMID 34324435Retrospective chart review with phone survey, no control groupn = 16 Adults with knee pain at one clinic14 of 16 reported relief (11 of 12 given BPC-157 alone, 3 of 4 given it with thymosin beta-4); no validated outcome measuresEvidence: Human observational evidence
Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study2024 PMID 39325560Uncontrolled single arm pilotn = 12 Women with interstitial cystitis unresponsive to pentosan polysulfateAll 12 reported symptom improvement after a single bladder wall injection; no adverse events reported; no control groupEvidence: Human observational evidence
Safety of intravenous infusion of BPC157 in humans: a pilot study2025 PMID 40131143Uncontrolled safety pilotn = 2 Two healthy adults who had received the peptide beforeNo measurable change in heart, liver, kidney, thyroid, or glucose markers and no side effects reported over 3 daysEvidence: Human observational evidence

Conditions studied

Conditions with evidence for BPC-157
ConditionGradeNote
Tendon injury and tendinopathyEvidence: Animal-only evidenceFaster Achilles tendon healing and increased tendon cell outgrowth in rats; no human RCT.
Muscle recovery and injuryEvidence: Animal-only evidenceFaster healing of transected and crushed muscle in rats; no human trial.
Wound healingEvidence: Animal-only evidenceFaster skin and gut wound closure in rodents.
Inflammation and inflammatory bowel diseaseEvidence: Animal-only evidenceProtection against NSAID and colitis models in rodents.
Inflammatory bowel disease (Crohn disease and ulcerative colitis)Evidence: Animal-only evidenceHealed colitis, fistula, and other gut lesion models in rats; no published human IBD trial.
Irritable bowel syndromeEvidence: Animal-only evidenceRodent gut injury models only; no human IBS study.
Traumatic brain injuryEvidence: Animal-only evidenceReduced injury severity in a mouse head trauma model; no human data.
OsteoarthritisEvidence: Animal-only evidenceRodent tendon, ligament, and muscle healing data; no cartilage or osteoarthritis study in humans.
Chronic painEvidence: Animal-only evidenceMarketed for joint and injury pain; rodent healing data only, with no human pain study.

Is BPC-157 legal in the United States?

Regulatory: HHS interim policy (draft)WADA: WADA prohibited

FDA and compounding status

BPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

  2. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

  3. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

  4. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  5. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

  6. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

  7. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

  8. WADA

    WADA 2022 Prohibited List adds BPC-157 as an S0 example

    The 2022 WADA Prohibited List took effect on January 1, 2022 and named BPC-157 as an example of a non-approved substance under section S0, making it prohibited at all times for athletes under the World Anti-Doping Code.

Full tracker for BPC-157 or the category-wide tracker.

Email me when BPC-157's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of BPC-157 used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Rodent studies gave BPC-157 by injection, in drinking water, or topically; animal doses do not translate to a human dose, and no human dose finding study has been published.

Routes reported

Routes of administration reported for BPC-157
#Route
1Subcutaneous injection (as sold)
2Oral capsule (as sold)
3Intraperitoneal, oral in water, and topical (animal studies)

BPC-157 side effects

Side effects

Side effects reported for BPC-157
#Reported side effect
1No systematic human safety data; three small uncontrolled pilot reports (about 30 people in total) reported no adverse events
2Injection site reactions reported anecdotally
3Nausea and dizziness reported anecdotally
4Theoretical concern about promoting growth of existing tumors because it stimulates angiogenesis through VEGFR2 in animal and cell studies (not demonstrated in humans)
5Unverified identity, purity, and sterility of products sold as research chemicals

Interactions

Interactions reported for BPC-157
#Interaction
1No formal human interaction studies exist
2Animal studies show BPC-157 modulates the nitric oxide system, so a theoretical interaction with nitrates, PDE5 inhibitors, and antihypertensives has been proposed but not tested

Contraindications

Contraindications for BPC-157
#Contraindication
1Active cancer or history of cancer (theoretical angiogenesis concern)
2Pregnancy and breastfeeding (no data)
3Competitive athletes subject to WADA testing (prohibited at all times under S0)

How do people access BPC-157 legally?

Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.

Access options

  • Conditional

    Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient BPC-157 by injection under the skin or into muscle, by mouth, or on the skin on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.

  • Not available

    Not available as an FDA approved product.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare BPC-157

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]

In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 as a single-ingredient product by subcutaneous or intramuscular injection, or in oral or topical forms, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put BPC-157 on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix BPC-157 with other peptides are not covered, and state rules still apply. [16] [17]

What FDA found

  • July 2026: FDA's review found websites of compounding pharmacies and of several US med spas and clinics that mentioned BPC-157, and said its data on how much it is compounded are limited. [21]
  • July 2026: The same review found an at-home BPC-157 injection kit sold with an optional telehealth consult. [21]
  • July 2026: The same review describes a patient who developed significant adverse reactions after using a BPC-157 and TB-500 injection labeled "for research purposes only". [21]
  • June 2023: FDA found an online seller taking orders for BPC-157 as an injectable and a nasal spray, and called it an unapproved new drug despite labels saying "not for human consumption". [22]
  • April 2020: FDA named BPC-157 among about 20 peptides and other bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [19]
  • July 2019: FDA told a state-licensed 503A pharmacy that drugs it compounded from BPC-157 acetate were not eligible for section 503A exemptions. The pharmacy said it would keep compounding with BPC-157. [23]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [18] [23] [24] [25] [26] [27]

What that means for you

  • A pharmacy that compounds BPC-157 relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [17]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [27]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [28]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [29] [30]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [25]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, BPC-157 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [27]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [31] [32] [33]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [20] [33] [34]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [27] [35] [36] [37] [38] [39]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [27]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [31]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
  • Pharmacy: Is this made for me on a prescription written in my name? [34]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [33]
  • Prescriber: What is the legal basis for a pharmacy to compound BPC-157? Is it FDA approved or on the 503A bulks list? [5] [27]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [28]

Blends that contain BPC-157

BPC-157 is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.

  • GLOW: with GHK-Cu, TB-500. No federal basis to compound.
  • KLOW: with GHK-Cu, TB-500, KPV. No federal basis to compound.
  • Wolverine stack: with TB-500. No federal basis to compound.

All peptide blends

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic peptide of 15 amino acids copied from a fragment of a protein in human gastric juice (stomach fluid). It is studied for tendon, muscle, and gut healing, almost entirely in rats. It is not an FDA approved drug, it is prohibited in sport, and PeptideAgent grades its evidence animal-only because no controlled human trial (one comparing treated people with an untreated or placebo group) has been published. [2] [4] [13]

BPC-157 benefits: what does the evidence show?

In rats, BPC-157 sped healing of cut tendons, muscles, ligaments, bone, and gut lesions, and it increased tendon cell growth and migration in lab studies (animal-only evidence). In people, the only published data are three small uncontrolled reports from one clinic: 14 of 16 people reported less knee pain after injections, and 12 women with interstitial cystitis reported improvement after one bladder injection. With no comparison group, those results cannot separate the peptide from placebo or natural recovery, so the benefits in humans are unproven. [1] [8] [9] [13]

What are the side effects of BPC-157, and is it safe?

Nobody knows how safe it is in people, because there is no systematic human safety data. The three small pilot reports (about 30 people) reported no adverse events, and rodent studies did not report toxicity, but that is far too little data to rule out uncommon or long term harms. Anecdotal reports mention injection site irritation, nausea, and dizziness. Products sold as research chemicals add their own risk, because their identity, purity, and sterility are not verified. [3] [10] [13] [14]

Does BPC-157 cause cancer?

There is no evidence that it does, and no study has tested the question. The concern is theoretical: in rats and in human blood vessel cells BPC-157 increased new blood vessel growth and VEGFR2 signaling, and tumors depend on new blood vessels. Human follow-up is limited to a few dozen people over short periods, which could not detect a cancer signal. People with active or past cancer are the group the theoretical concern applies to most, and reviewers advise treating it as investigational. [12] [14]

Oral BPC-157 vs injection: what did studies use?

Rodent studies gave BPC-157 by injection, in drinking water, and on the skin, and reported activity by mouth in animals. The human pilot reports all used injections (into the knee, the bladder wall, or a vein). No study has measured how much oral BPC-157, including the arginate salt form, is absorbed in people. In rats and dogs, injected BPC-157 had a half-life under 30 minutes and was quickly broken down into amino acids. [4] [11] [14]

Is BPC-157 FDA approved?

No. BPC-157 is not FDA approved for any use. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient BPC-157 by injection under the skin or into muscle, by mouth, or on the skin on a patient-specific prescription, under strict quality and reporting conditions. That is not an FDA approval or a bulks listing, it is not binding, and HHS may revisit it. Products sold as research chemicals for human use are still unapproved drugs. [5] [6] [15] [16] [17]

Does BPC-157 help muscle growth?

No study shows that it does. The rodent muscle studies are about healing injured muscle, not building new muscle in healthy animals, and no human study has measured muscle size or strength. A 2025 systematic review noted increased growth hormone receptor expression in lab studies, which is often cited online, but that is a cell finding, not a measured gain in muscle. It is also prohibited at all times for tested athletes. [7] [13]

Is BPC-157 banned by WADA?

Yes. BPC-157 is prohibited at all times under section S0 (non-approved substances) of the WADA Prohibited List, because it has no current approval by any government health authority for human use. Athletes subject to testing should not use it. [7]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

More on the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
  2. [2]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
  3. [3]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
  4. [4]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  8. [8]Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021PubMed 34324435, 2021
  9. [9]Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024PubMed 39325560, 2024
  10. [10]Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025PubMed 40131143, 2025

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, November 1). BPC-157: evidence, legality, and access. https://peptideagent.ai/peptides/bpc-157
HTML link
<a href="https://peptideagent.ai/peptides/bpc-157">BPC-157: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.